Tag
An interventional study reveals testosterone’s tissue-specific effects on lipid metabolism, highlighting skeletal muscle as a critical site of metabolic disruption in male hypogonadism and its cardiometabolic implications.
This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.
A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offeri
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be
Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlin
In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference
This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.
Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.
